SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Talis Biomedical Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 8, 2022 - (NASDAQ: TLIS)

NEW YORK, March 2, 2022

Shareholders who purchased shares of TLIS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/talis-biomedical-corporation-loss-submission-form/?id=24152&from=4

CLASS PERIOD: This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 2021 initial public offering.

ALLEGATIONS: According to the lawsuit, documents that the Company issued in connection with its IPO failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis's Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company's commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

DEADLINE: March 8, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/talis-biomedical-corporation-loss-submission-form/?id=24152&from=4